Supplemental Methods from Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R–YAP Axis

Hong Zhu,Dan-Dan Wang,Tao Yuan,Fang-Jie Yan,Chen-Ming Zeng,Xiao-Yang Dai,Zi-bo Chen,Ying Chen,Tianyi Zhou,Guang-Han Fan,Meidan Ying,Ji Cao,Peihua Luo,Xi-Jie Liu,Yuandong Hu,Yong Peng,Qiaojun He,Bo Yang

DOI: https://doi.org/10.1158/0008-5472.22417226.v1

2023-01-01

Abstract:Materials and Methods for Supplemental Figures

What problem does this paper attempt to address?

Supplemental Figures and Legends from Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R–YAP Axis

Hong Zhu,Dan-Dan Wang,Tao Yuan,Fang-Jie Yan,Chen-Ming Zeng,Xiao-Yang Dai,Zi-bo Chen,Ying Chen,Tianyi Zhou,Guang-Han Fan,Meidan Ying,Ji Cao,Peihua Luo,Xi-Jie Liu,Yuandong Hu,Yong Peng,Qiaojun He,Bo Yang

DOI: https://doi.org/10.1158/0008-5472.22417229

2023-01-01

Abstract:Supp Figure 1. The treatment of CT-707 reduced the protein level of CTGF under hypoxia. Supp Figure 2. CT-707 elicited apoptotic cell death but not cell cycle arrest under hypoxia. Supp Figure 3. The protein level of HIF-1α under hypoxia was not influenced by YAP depletion by siRNA. Supp Figure 4. FAK inhibition was not required for the hypoxic activity of CT-707. Supp Figure 5. The semi-quantitative analyses using density measurements on the protein levels displayed in Figure 5. Supp Figure 6. The correlation of FAK, IGF-1R and YAP target genes expression with the overall survival days of liver cancer patients. Supp Figure 7. The in vivo activities of CT-707 on HepG2-, Bel-7402-xenograft and H22-allograft models. Supp Figure 8. PF-562271 treatment caused death of HepG2-xenografted nude mice but imposed less activity than CT-707.
Supplemental Tables from Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R–YAP Axis

Hong Zhu,Dan-Dan Wang,Tao Yuan,Fang-Jie Yan,Chen-Ming Zeng,Xiao-Yang Dai,Zi-bo Chen,Ying Chen,Tianyi Zhou,Guang-Han Fan,Meidan Ying,Ji Cao,Peihua Luo,Xi-Jie Liu,Yuandong Hu,Yong Peng,Qiaojun He,Bo Yang

DOI: https://doi.org/10.1158/0008-5472.22417223.v1

2023-01-01

Abstract:Supplemental Table 1. The primer sequences for qRT-PCR assay Supplemental Table 2. The targeting sequences for siRNA Supplemental Table 3. The list of compounds for YAP-TEADs luciferase screening
Supplementary Methods, Figures 1-4 from Rho Kinase Phosphorylation Promotes Ezrin-Mediated Metastasis in Hepatocellular Carcinoma

Yong Chen,Dongmei Wang,Zhen Guo,Jun Zhao,Bing Wu,Hui Deng,Ti Zhou,Hongjun Xiang,Fei Gao,Xue Yu,Jian Liao,Tarsha Ward,Peng Xia,Chibuzo Emenari,Xia Ding,Winston Thompson,Kelong Ma,Jingde Zhu,Felix Aikhionbare,Kefen Dou,Shi-Yuan Cheng,Xuebiao Yao

DOI: https://doi.org/10.1158/0008-5472.22387211

2023-01-01

Abstract:Supplementary Methods, Figures 1-4 from Rho Kinase Phosphorylation Promotes Ezrin-Mediated Metastasis in Hepatocellular Carcinoma
Supplementary Methods from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Mengyu Xie,Hong Zheng,Ranjna Madan-Lala,Wenjie Dai,Nicholas T. Gimbrone,Zhihua Chen,Fumi Kinose,Sarah A. Blackstone,Keiran S.M. Smalley,W. Douglas Cress,Eric B. Haura,Uwe Rix,Amer A. Beg

DOI: https://doi.org/10.1158/0008-5472.22422753

2023-01-01

Abstract:Supplementary Methods for Xie et al, MEK inhibition modulates cytokine response to mediate therapeutic efficacy in lung cancer
Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft model

Yun-Qing Qiu,Jue Zhou,Xin-Shan Kang,Lie-Ming Ding,Wei Yu,Fen-Lai Tan,Dan-Feng Deng

DOI: https://doi.org/10.1038/srep04324

IF: 4.6

2014-01-01

Scientific Reports

Abstract:The present study was to synthesize a novel multi-targeted kinase inhibitor and evaluated its anticancer effects on a hepatocellular carcinoma xenograft model. In our study, in vivo efficacy was determined in nude mice bearing HuH7 human HCC xenografts. The mice were randomly divided into the following five groups with the use of a randomization chart (n = 8 in each group): high-dose BZG-4000 group, medium-dose BZG-4000 group, low-dose BZG-4000 group, sorafenib group and model group. Tumor size measurements included the length (L) and width (W) measured with calipers and tumor volume was calculated as (LW ∧ 2)/2. Tumor tissues slides were hematoxylin and eosin (HE) stained for histopathological examination. Immunohistochemistry detected CD31 expression and Western blotting measured VEGF protein expression. We found that when BZG-4000 was administered orally to xenograft HuH7 nude mice, tumor growth was inhibited and significant tumor shrinkage was evident. After oral administration of BZG-4000 at 40 mg/kg/day, the tumor weight and volume were significantly lower than tumors of the sorafenib group. BZG-4000 considerably decreased the expression of CD31 and VEGF in tumors compared to tumors treated with positive control drug. It was concluded that BZG-4000 has the potential to inhibit the tumorigenesis of hepatocellular carcinoma in vivo by decreasing the expression of CD31 and VEGF.
Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Alfred S.L. Cheng,Suki S. Lau,Yangchao Chen,Yutaka Kondo,May S. Li,Hai Feng,Arthur K. Ching,Kin F. Cheung,Hoi K. Wong,Joanna H. Tong,Hongchuan Jin,Kwong W. Choy,Jun Yu,Ka F. To,Nathalie Wong,Tim H.-M. Huang,Joseph J.Y. Sung

DOI: https://doi.org/10.1158/0008-5472.22395239.v1

2023-01-01

Abstract:Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis
Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Junying Zeng,Sharad Sharma,Yong‐Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming-Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22503690

2023-01-01

Abstract:PDF - 71K, Legends for Supplementary Figures 1 through 5.
Supplementary Material and Methods from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Huai-Xiang Hao,Hongyun Wang,Chen Liu,Steven Kovats,Roberto Velazquez,Hengyu Lu,Bhavesh Pant,Matthew D. Shirley,Matthew J. Meyer,Minying Pu,Joanne Lim,Michael J. Fleming,LeighAnn Alexander,Ali Farsidjani,Matthew J. LaMarche,Susan E. Moody,Serena J. Silver,Giordano Caponigro,Darrin D. Stuart,Tinya J. Abrams,Peter S. Hammerman,Juliet A. Williams,Jeffrey A. Engelman,Silvia Goldoni,Morvarid Mohseni

DOI: https://doi.org/10.1158/1535-7163.22505919.v1

2023-01-01

Abstract:Supplementary Material and Methods. File contains the following: Transcriptome sequencing and analysis, Soft agar assay, 2D and 3D Cell proliferation screen and compound characterization information.
Supplementary Methods and Supplementary Figures 1 Through 9 from A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth in Vitro and in Vivo

Fardokht A. Abulwerdi,Chenzhong Liao,Meilan Liu,Asfar S. Azmi,Amro Aboukameel,Ahmed S.A. Mady,Thippeswamy Gulappa,Tomasz Cierpicki,Scott Owens,Tao Zhang,Duxin Sun,Jeanne A. Stuckey,Ramzi M. Mohammad,Zaneta Nikolovska‐Coleska

DOI: https://doi.org/10.1158/1535-7163.22500082.v1

2023-01-01

Abstract:PDF - 3347KB, Synthesis and characterization of the lead compound 1 (UMI-59) and its analog 2 (UMI-77), additional details for used methods, and nine supplementary figures.
Supplementary Figures 1-3 from OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models

Andrew J. Garton,Andrew P.A. Crew,Maryland Franklin,Andrew R. Cooke,Graham M. Wynne,Linda Castaldo,Jennifer Kahler,Shannon L. Winski,April Franks,Eric N. Brown,Mark A. Bittner,John F. Keily,Paul Briner,Chris Hidden,Mary C. Srebernak,Carrie Pirrit,Matthew O'Connor,Anna Chan,Bojana Vulevic,Dwight Henninger,Karen Hart,Regina Sennello,An-Hu Li,Tao Zhang,Frank Richardson,David L. Emerson,Arlindo L. Castelhano,Lee D. Arnold,Neil W. Gibson

DOI: https://doi.org/10.1158/0008-5472.22366923

2023-01-01

Abstract:Supplementary Figures 1-3 from OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models
Supplementary Methods from AZ1366: an Inhibitor of Tankyrase and the Canonical Wnt Pathway That Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition

Hannah A. Scarborough,Barbara A. Helfrich,Matias Casás-Selves,Alwin G. Schuller,Shaun E. Grosskurth,Jihye Kim,Aik-Choon Tan,Daniel C. Chan,Zhiyong Zhang,Vadym Zaberezhnyy,Paul A. Bunn,James DeGregori

DOI: https://doi.org/10.1158/1078-0432.22463952

2023-01-01

Abstract:Supplementary methods and materials
Supplementary Methods, Figures 1-3 from Synergistic Antitumor Activity of Gemcitabine and ABT-737 in Vitro and in Vivo Through Disrupting the Interaction of USP9X and Mcl-1

Chong Zhang,Tian-yu Cai,Hong Zhu,Liu-qing Yang,Hai Jiang,Xiao-wu Dong,Yong-zhou Hu,Neng-ming Lin,Qiao-jun He,Bo Yang

DOI: https://doi.org/10.1158/1535-7163.22496977

2023-01-01

Abstract:Supplementary Methods, Figures 1-3 from Synergistic Antitumor Activity of Gemcitabine and ABT-737 In Vitro and In Vivo through Disrupting the Interaction of USP9X and Mcl-1
Legend for Supplementary Figures from Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma

Tongxin Liu,Quanquan Sun,Qi Li,Hua Yang,Yuqin Zhang,Rong Wang,Xiaoshan Lin,Dong Xiao,Yawei Yuan,Longhua Chen,Wei Wang

DOI: https://doi.org/10.1158/1535-7163.22502823

2023-01-01

Abstract:Supplementary Figure legends
Supplementary Figure 5 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

Amanda Herzog,Yansong Bian,Robert Vander Broek,Bradford Hall,Jamie Coupar,Hui Cheng,Anastasia L. Sowers,John D. Cook,James B. Mitchell,Zhong Chen,Ashok B. Kulkarni,Carter Van Waes

DOI: https://doi.org/10.1158/1078-0432.22445265

2023-01-01

Abstract:PDF file - 1957K, Treatment in UM-SCC xenograft and Tgfbr1/Pten KO mice.
CT-707 Overcomes Hypoxia-mediated Sorafenib Resistance in Hepatocellular Carcinoma by Inhibiting YAP Signaling

Chen Zibo,Yuan Tao,Yan Fangjie,Ye Song,Xie Qin,Zhang Bo,Lin Nengmin,He Qiaojun,Yang Bo,Zhu Hong

DOI: https://doi.org/10.1186/s12885-022-09520-5

IF: 4.638

2022-01-01

BMC Cancer

Abstract:Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. Sorafenib is the first-line treatment for advanced HCC, but the anti-cancer effects remain to be improved as indicated by its low response rates and failure to prolong the progression-free survival (PFS). Thus, it is urgent to explore approaches to improve the clinical outcome. Materials and methods: The effect of Sorafenib in HCC was analyzed by SRB (sulforhodamine B) assay in normoxia and hypoxia, respectively. The different dose combination effect of CT707 and sorafenib was analyzed by SRB assay in hypoxia. Flow cytometry assay was used to detect the cell apoptosis rate with CT707 and sorafenib treatment in hypoxia. Western blotting was used to detect the expression levels of apoptosis -related proteins and the mechanism of CT707 overcome the resistance of sorafenib in hypoxia. Results: Our study showed that the characteristic intratumor hypoxia of advanced HCC is one of the major factors which mediated the drug resistance towards sorafenib in HCC. And CT-707, a novel multi-kinase inhibitor, could sensitize the hypoxic HCC cells towards sorafenib. Further studies showed that CT-707 abolished the nuclear translocation of Yes Associate-Protein (YAP), which has been demonstrated as one of mechanism of hypoxia-mediated sorafenib-resistance in HCC. Conclusions: Overall, this study not only favors the development of this novel multi-kinase inhibitor CT-707 as a therapeutic agent against HCC, but also provides a potential strategy to overcome the hypoxia-mediated resistance to sorafenib in HCC patients.
Supplementary Figure 2 from Dual Inhibition of PI3K and Mtor Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer

Xiaosong Chen,Meizhong Zhao,Mingang Hao,Xueqing Sun,Jinglong Wang,Yan Mao,Lidong Zu,Junjun Liu,Yandong Shen,Jianhua Wang,Kunwei Shen

DOI: https://doi.org/10.1158/1541-7786.22510113.v1

2023-01-01

Abstract:PDF file - 471K, Growth-inhibitory effects of tamoxifen, everolimus, and various PI3K inhibitors on breast cancer cell lines.
Supplementary Figures 1-6 from Combined EGFR/MET or EGFR/HSP90 Inhibition is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

Lu Xu,Eiki Kikuchi,Chunxiao Xu,Hiromichi Ebi,Dalia Ercan,Katherine A. Cheng,Robert Padera,Jeffrey A. Engelman,Pasi A. Jänne,Geoffrey I. Shapiro,Takeshi Shimamura,Kwok-Kin Wong

DOI: https://doi.org/10.1158/0008-5472.22391819.v1

2023-01-01

Abstract:PDF file - 1.4MB, Supplemental Figure 1. MET is inducible in MET, TD/MET, and TL/MET models Supplemental Figure 2. Quantification of hMET expression in mouse models Supplemental Figure 3. Comparison of the tumor counts in mutant EGFR lung tumors with or without expression of hMET. Supplemental Figure 4. Representative MRI images prior to and after treatment in TL and TL/MET mice. Supplemental Figure 5. Xenografts of HCC827GR6 cells ectopically expressing EGFR E746_A750del/T790M are sensitive to the combination of WZ4002 and 17-DMAG. Supplemental Figure 6. The WZ4002/crizotinib or WZ4002/17-DMAG combinations suppress phosphorylation of EGFR, Akt, and Erk in TD and TD/MET to a greater extent than individual treatments
Supplementary Figures from Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function

Rui Jin,Liang Liu,Yun Xing,Tao Meng,Li Ma,Jinpeng Pei,Ying Cong,Xuesai Zhang,Zhiqiang Ren,Xin Wang,Jingkang Shen,Ker Yu

DOI: https://doi.org/10.1158/1535-7163.22519333

2023-01-01

Abstract:Supplementary Figures and Tables
Supplemental Methods from Hypoxia Promotes Breast Cancer Cell Growth by Activating a Glycogen Metabolic Program

Ke Tang,Liyan Zhu,Jie Chen,Dianheng Wang,Liping Zeng,Chen Chen,Liang Tang,Li Zhou,Keke Wei,Yabo Zhou,Jiadi Lv,Yuying Liu,Huafeng Zhang,Jingwei Ma,Bo Huang

DOI: https://doi.org/10.1158/0008-5472.22430541

2023-01-01

Abstract:Supplemental Methods
Supplemental Materials and Methods from Targeting TAZ-Driven Human Breast Cancer by Inhibiting a SKP2-p27 Signaling Axis

He Shen,Nuo Yang,Alexander Truskinovsky,Yanmin Chen,Ashley L. Mussell,Norma J. Nowak,Lester Kobzik,Costa Frangou,Jianmin Zhang

DOI: https://doi.org/10.1158/1541-7786.22516207

2023-01-01

Abstract:Supplemental materials and methods

Supplemental Methods from Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R–YAP Axis

Supplemental Figures and Legends from Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R–YAP Axis

Supplemental Tables from Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R–YAP Axis

Supplementary Methods, Figures 1-4 from Rho Kinase Phosphorylation Promotes Ezrin-Mediated Metastasis in Hepatocellular Carcinoma

Supplementary Methods from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft model

Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Material and Methods from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Supplementary Methods and Supplementary Figures 1 Through 9 from A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth &lt;i&gt;in Vitro&lt;/i&gt; and &lt;i&gt;in Vivo&lt;/i&gt;

Supplementary Figures 1-3 from OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models

Supplementary Methods from AZ1366: an Inhibitor of Tankyrase and the Canonical Wnt Pathway That Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition

Supplementary Methods, Figures 1-3 from Synergistic Antitumor Activity of Gemcitabine and ABT-737 in Vitro and in Vivo Through Disrupting the Interaction of USP9X and Mcl-1

Legend for Supplementary Figures from Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma

Supplementary Figure 5 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

CT-707 Overcomes Hypoxia-mediated Sorafenib Resistance in Hepatocellular Carcinoma by Inhibiting YAP Signaling

Supplementary Figure 2 from Dual Inhibition of PI3K and Mtor Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer

Supplementary Figures 1-6 from Combined EGFR/MET or EGFR/HSP90 Inhibition is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

Supplementary Figures from Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function

Supplemental Methods from Hypoxia Promotes Breast Cancer Cell Growth by Activating a Glycogen Metabolic Program

Supplemental Materials and Methods from Targeting TAZ-Driven Human Breast Cancer by Inhibiting a SKP2-p27 Signaling Axis

Supplementary Methods and Supplementary Figures 1 Through 9 from A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth <i>in Vitro</i> and <i>in Vivo</i>